Awardee OrganizationUNIVERSITY OF CALIFORNIA RIVERSIDE
Description
Abstract Text
Plasmodium falciparum contributes to 1.5-2.7 million deaths annually. Cerebral malaria, a complication of P. falciparum infections, is associated with sequestration of erythrocytes in the blood vessels of the brain and is due to the adhesion of malaria-infected erythrocytes (PE) to the endothelial cells (EC) lining the microcirculation. Sequestration of PE in the placenta of pregnant women leads to complications that include low fetal birth weight and an increased risk of death. At present none of the therapies for malaria specifically target the adhesive phenomena associated with sequestration. Describing the molecular architecture of the PE and EC surfaces is critical to understanding the mechanisms that lead to sequestration and for developing anti-adhesive treatments. It is known that increased adhesiveness of the PE is due to parasite-induced changes in the erythrocyte membrane protein, band 3, as well as the surface exposure of parasite-encoded proteins. Though the amino acid sequences of band 3 critical to adhesion have been identified it is not known how this adhesin is formed. To define the possible role of band 3 aggregation and/or proteolysis in inducing conformational change, the lateral distribution of band 3 within the bilayer will be evaluated by freeze fracture microscopy and coordinated with electron micrographic immunolocalization of adhesive sites, as well as by the use of fluorescence photobleaching recovery, polarized fluorescence depletion and luminescence quenching. In addition, to biochemically characterize the structural changes in band 3 that could influence the disposition of adhesive sequences, attempts will be made to isolate truncated forms of band 3 and cleavage sites identified. Immunoprecipitation, immunoblotting as well as competitive inhibition of antibody binding will be used to identify common adhesive motifs in the band 3-related and the parasite-encoded adhesin Plasmodium falciparum erythrocyte membrane protein-1; estimates of their contribution to cytoadherence will be determined. Other PE adhesins as well as EC ligands of microvessels in the human brain, dermis and bone marrow that bind PE will be identified and characterized through the use of monoclonal antibodies, phage display and synthetic combinatorial library technologies, and peptide affinity chromatography. Once identified, it should be possible to design drugs (i.e. peptidomimetics, small molecules, antibodies) that could inhibit or reverse sequestration thus allowing for better and safer therapeutic modalities for individuals suffering from falciparum malaria.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
627797426
UEI
MR5QC5FCAVH5
Project Start Date
01-February-2000
Project End Date
31-January-2006
Budget Start Date
01-February-2004
Budget End Date
31-January-2006
Project Funding Information for 2004
Total Funding
$264,010
Direct Costs
$178,990
Indirect Costs
$85,020
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Allergy and Infectious Diseases
$264,010
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI043608-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI043608-05
Patents
No Patents information available for 5R01AI043608-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI043608-05
Clinical Studies
No Clinical Studies information available for 5R01AI043608-05
News and More
Related News Releases
No news release information available for 5R01AI043608-05
History
No Historical information available for 5R01AI043608-05
Similar Projects
No Similar Projects information available for 5R01AI043608-05